Overall, Cathepsin D showed a notable decrease in GRN and C9orf72 carriers associated with disease progression and elevated copy number in C9orf72, thus signifying mutant gene carriers and pathological conditions, thereby functioning as a potential biomarker for screening and early detection of familial FTD. This evidence concerns the gene GRN and frontotemporal dementia.